Table 1—

Main characteristics and results of the eligible studies

First author [Ref. no.]YearHistologyStageN ptsTechniqueHR estimationResults
Dazzi 181989NSCLCI–?152IHCNo dataNS
Veale 231993NSCLCI–III19Ligand competitionHR+CI 95%Negative
Tateishi 291994AdenocarcinomaI–IV119IHCSurvival curvesNS
Giatromanolaki 111996NSCLCI–II107IHCNo dataNS
Koukourakis 191997NSCLCI–II107IHCNo dataNS
Pastorino 141997NSCLCI505IHCHR+CI 95%NS
Rusch 221997NSCLCI–IIIA96Northern+IHCSurvival curvesPositive
Greatens 241998NSCLCI–IV101IHCNo dataNS
Pfeiffer 171998NSCLCI–IV180IHCSurvival curvesNS
Volm 201998SquamousI–III121IHCSurvival curvesNegative
Fontanini 211998NSCLCI–IIIA195IHCLogrank+N eventsNS
Fu 121999NSCLCI–IIIB158IHCNo dataNS
D'Amico 131999NSCLCI408IHCLogrank+N eventsNS
Ohsaki 162000NSCLCI–IV290IHCSurvival curvesNegative
Cox 92000NSCLCI–IIIA169IHCLogrank+N eventsNS
Brabender 102001NSCLCI–IIIA83PCRHR+CI 95%NS
  • N pts: number of patients

  • HR: hazard ratio

  • NSCLC: nonsmall-cell lung cancer

  • IHC: immunohistochemistry

  • PCR: polymerase chain reaction

  • CI: confidence interval

  • NS: nonsignificant